"gain vision" is a correct and usable phrase in written English.
It can be used to describe the act or process of obtaining or improving one's ability to see or understand something. Example: After struggling with his studies for years, John finally gained vision and was able to see the solution to the complex equation.
One reason that Molyneux's problem could be posed in the first place is the dearth of human subjects who gain vision after extended congenital blindness.
It seeks to influence policy and strategy in its advocacy of action research as a primary means to gain vision and leverage in wicked problem areas.
This indicates that patients who previously received vPDT could still gain vision when switched to ranibizumab.
In our study, visual improvement was achieved in those eyes previously classified in our schema as having the potential to gain vision with only CLET.
20, 21 Pegaptanib was shown in a Phase II randomized controlled trial to decrease vision loss and increase vision gain compared to a sham medication, with a decreased need for subsequent photocoagulation.
In "Poor Miss Finch, Collinss's description of the reactions of a person gaining vision for the first time after having been blind from birth (something extremely rare in his time, although it was discussed by thinkers like John Locke) has been praised for its psychological understanding.
A spokeswoman for Novartis said the company would continue to work with NICE and the Department of Health to "ensure appropriate patients are able to receive this very important treatment, which in clinical trials has been shown to double the likelihood of gaining vision and reduce the chance of losing vision by up to three-fold compared to laser treatment".
At 6 months, 61.1% (22/36) showed stable or gaining vision, and 27.8% (10/36) gained three or more lines.
After a single session of triple therapy, 66.7% and 61.1% achieved stable or gaining vision 3 and 6 months, respectively.
The proportion of subjects maintaining or gaining vision from baseline to week 54 was nominally considered the primary efficacy endpoint.
Results of this study demonstrated that 100% of subjects remained visually stable and 84.6% gained vision after switching to this dosing regimen.
